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Objective To determine whether varenicline, a recently
licensed smoking cessation product, is associated with
an increased risk of suicide and suicidal behaviour
compared with alternative treatments bupropion and
nicotine replacement therapy.
Design Cohort study nested within the General Practice
Research Database.
Setting Primary care in the United Kingdom.
Participants 80660 men and women aged 18-95 years
were prescribed a new course of a smoking cessation




Main outcome measures Primary outcomes were fatal
and non-fatal self harm, secondary outcomes were
suicidal thoughts and depression, all investigated with
Cox’s proportional hazards models.
Results There was no clear evidence that varenicline was
associated with an increased risk of fatal (n=2) or non-
fatal(n=166)selfharm,althoughatwofoldincreasedrisk
cannot be ruled out on the basis of the upper limit of the
95% confidence interval. Compared with nicotine
replacement products, the hazard ratio for self harm
among people prescribed varenicline was 1.12 (95% CI
0.67 to 1.88), and it was 1.17 (0.59 to 2.32) for people
prescribed bupropion. There was no evidence that
varenicline was associated with an increased risk of
depression (n=2244) (hazard ratio 0.88 (0.77 to1.00)) or
suicidal thoughts (n=37) (1.43 (0.53 to 3.85)).
ConclusionAlthoughatwofoldincreasedriskofselfharm




There are growing concerns that varenicline, a smok-
ingcessationproductlicensedintheUKsinceSeptem-
ber 2006, may be associated with an increased risk of
suicide.Vareniclineisapartialagonistthatbindsatthe
nicotinic α4β2 receptor, and it seems to be the most
effective smoking cessation product currently
available.
1 As it acts on the central nervous system
and its effects include the stimulation of dopamine
release, it is possible that it may have an impact on
mood and suicide risk.
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In December 2007, after reports of depression and
suicidal thoughts among people prescribed vareni-
cline, the Medicines and Healthcare Products Regula-
tory Agency (MHRA) issued a warning concerning
possible increased risks,
4 with further warnings issued
in July and November 2008. Similar warnings have
been issued by regulatory authorities worldwide, and
warnings have been added to the prescribing informa-
tion and information for patients. In July 2009, the US
Food and Drugs Administration (FDA) required the
manufacturers of both varenicline and bupropion to
add a new “boxed warning” (the strongest warning
that the FDA requires) to the product labelling based
on the continued review of postmarketing adverse
event reports. By June 2008, almost half a million peo-
ple had been prescribed varenicline in the UK. The
rate of reported suicide related events tripled in the
months immediately after regulatory warnings in the
UK (see figure), a phenomenon known as “stimulated
reporting.”ByApril2009,yellowcardreportsrelating
to 14 suicides in people taking varenicline had been
received by the MHRA, although causal links were
not confirmed.
Although clinician and patient reports of adverse
events associated with varenicline suggest the possibi-
lity of serious side effects, controlled studies are
required to quantify the degree of risk, distinguish the
side effects of varenicline from the effects of smoking
cessation, and take account of the characteristics of
people who decide to stop smoking (confounding by
indication). To our knowledge, no previous large
population studies have investigated this issue.





by alcohol misuse and mental illness seems to explain
much of the association.
2 One way of distinguishing
any increased risk associated with varenicline from
thatassociatedwithsmokingcessationperseistocom-
pare the risk of self harm among people taking
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cessationproducts—nicotinereplacementtherapyand
bupropion.Inthispaperwereportacohortstudyusing
the UK General Practice Research Database (GPRD)
to investigate this issue.
METHODS
Cohort identification
The GPRD records demographic, consultation, pre-
scribing,referralandhealthoutcomedatafromalmost
500generalpractices(about3.6millionactivepatients)
throughout the United Kingdom (www.gprd.com/
home/default.asp). Data quality are checked and vali-
dated by the GPRD Group, and previous studies con-
firm good completenessofrecordingof clinicaldata.
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It is likely that almost all prescriptions issued by the
general practitioners are recorded on the database, as
they generate prescriptions using their computer, and
these are automatically captured in the computer
record.
We identified all patients aged 18 years and over
with GPRD records who were prescribed either vare-
nicline (recommended treatment duration 12 weeks),
bupropion (recommended treatment duration
7-9 weeks), or a nicotine replacement product (trans-
dermal patch, inhaler, nasal spray, gum, sublingual
tablet or lozenge—variable recommended treatment
durations, approximate range 3-6 months) between 1
September2006 and 31 May 2008. We chose 18 years
as the lower age limit for inclusion in our study as the
drug is licensed for use only in adults. We excluded all
patients(n=1376)whotookaparticularsmokingcessa-




over the period of the prescription and for three
months after the date of the last prescription. We
excluded patients with GPRD records of <365 days
before their first recorded prescription. We used only
those patients classified as “acceptable” by the GPRD
and restricted the analysis to practices that were desig-
nated as “up to standard” by the GPRD Group. This
procedure was implemented to maximise the quality
and completeness of the data. Patients were cate-
gorised to the three exposure groups (varenicline,
bupropion, or nicotine replacement therapy) based
on the drug they were first prescribed in the follow-
up period. Subsequent treatment episodes were not
included in the analysis, but we identified patients
who received other smoking cessation treatments
after the index prescription and censored follow-up at
the time of switching or adding products. We did a
sensitivity analysis by dropping all people who com-
menced other smoking cessation products.
Power calculations based on preliminary data extra-
cts from the GPRD indicated we had sufficient (80%)
power (5% level of statistical significance) to detect
twofold increases in risk of self harm with varenicline
compared with other products.
Outcome measures
Our primary outcome was fatal and non-fatal self
harm. This was defined based on more than 70 Read
codes and Oxford Medical Information System
(OXMIS) medical terms using an algorithm used in a
previous GPRD study.
9 Read and OXMIS are coding
systems used by general practices to enter diagnoses:
the codes used included terms such as “poisoning self-
inflicted”, “intentional self-harm by hanging, strangu-
lation/suffocation”, “intentional self-harm by sharp
object”, and “attempted suicide” (the full list is avail-
able from the authors). Suicide deaths were identified
from death details and postmortem findings recorded
on GPRD. We did not obtain death certificates for all
deaths.
Wealsoexaminedassociationsofsmokingcessation
products with suicidal thoughts, depression, and all
cause mortality, again using relevant Read and
OXMIS terms; we defined depression as the start of
antidepressanttherapyandexcludedfromthisanalysis
peoplewhohadbeenprescribedantidepressantsatany




age (five age groups of 18-30, 31-40, 41-50, 51-60,
>60 years); previous psychiatric consultation; alcohol
misuse; current (at the time of starting smoking cessa-
tion product) or previous use of psychotropic medica-
tion (hypnotics, antipsychotics, or antidepressants
(British National Formulary classes 4.1, 4.2, and 4.3
respectively)); previous self harm or suicidal thoughts;
previousprescriptionsforsmokingcessationproducts;
numberofGP visitsperyear(to controlforpropensity
to consult and so report symptoms; four categories of
≤1.8, >1.8-3.1, >3.1-5.2, and >5.2 average consulta-
tions/year); whether initial exposure occurred before


















































Fig 1 | Rate of suicide related adverse events reported for
varenicline per million tablets prescribed in 2007-2008. (Data
source MHRA yellow cards and data derived from IMS HEALTH
Midas database)
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effects with varenicline; index of multiple deprivation
(an ecological measure of socioeconomic position
including area levels of income, employment, educa-
tion, and a range of other factors (five levels))
10; region
of the UK (England, Northern Ireland, Scotland, or
Wales);andwhetherothersmokingcessationproducts
were prescribed after the index prescription. There
were no missing data for these possible confounders.
Analysis
We used Cox proportional hazards regression models
in Stata, release 9.2 (StataCorp, College Station, TX,
USA) for all analyses. We used calendar time since
starting the product as the time axis and linked this to
prescription duration to identify “current exposure.”
Follow-up began on the date of the first prescription
of a smoking cessation product after 1 September
2006 and ended three months after the date of the last
prescription or with a primary end point (fatal or non-
fatal self harm). Patients who died from causes other
than suicide, who left their practice, or who started
another smoking cessation product during the
exposure period were censored on the relevant dates.
The last date that the practice contributed data to the
GPRDwasalsoincorporatedintothecensoring.Inour
initial models we controlled for age and sex, we then
assessed the effect of controlling for all the confound-
ingfactorslistedabove,fittedascategoricalvariablesto
the models.
We conducted separate analyses in relation to the
other study end points (suicidal thoughts and depres-
sion). In these analyses subjects who died or left the
practicewerecensoredontheirdatesofdeathordepar-
ture. We used nicotine replacement therapy as the
baseline (reference) category for our risk estimates as
mostpatientswereprescribedtheseproductsandmost
episodes of self harm occurred in this group.
By fitting appropriate interaction terms to the mod-
els, we investigated whether any associations differed
by sex; age (five categories); calendar year of prescrip-
tion (in view of changes in the Summary of Product
CharacteristicsandBritishNationalFormularywarnings
concerning varenicline and publication of the Drug
Safety Update influencing prescribing patterns and
reporting in 2007-8); and past psychiatric history or
treatment with psychotropic drugs.
We investigated the proportional hazards assump-
tion graphically. For some confounders where there
was some graphical evidence that the proportionality
assumptionswereviolated,wefittedmodelswiththese
variables as strata. The effects on the model estimates
for the smoking cessation therapies were minimal and
in the final analysis no stratification was used.
RESULTS
Altogether 80660 patients were prescribed a new
course of a smoking cessation product over the study
period: the first treatment prescribed was a nicotine
replacement product (n=63265), bupropion (n=6422),
or varenicline (n=10973). Total exposure time was
24055.6 person years: 18879.2 person years for nico-
tine replacement therapies (mean 15.5 weeks per per-
son); 1690.8 person years for bupropion (mean
13.7 weeks per person), and 3485.6 person years for
varenicline (mean 16.5 weeks per person).
Thecharacteristicsofpatientsprescribedvarenicline
were similar to those prescribed bupropion (table 1).
Compared with patients prescribed nicotine replace-
mentproducts,patientsprescribedbupropionandvar-
enicline were more often male and less likely to have a
historyofpsychiatric consultation,alcoholmisuse,use
of psychotropic medication, or self harm or suicidal
thoughts. People prescribed bupropion were younger
than those prescribed the other products, but the
differences were slight. Altogether, 9.5% of patients
prescribed varenicline had previously harmed them-
selves or experienced suicidal thoughts. Almost half
of all patients had previously been prescribed a smok-
ing cessation product.
Self harm and suicidal thoughts
Over the follow-up period there were 166 episodes of
non-fatal self harm (154 (93%) being cases of self poi-
soning), two suicides (both in patients prescribed nico-
tine replacement products, one by means of hanging,
the other with a firearm), and 37 episodes of suicidal
thoughts. The incidence of self harm, standardised for
age and sex, was 533.1 (95% confidence interval 277.0
to 789.2) per 100000 person years in patients pre-
scribed varenicline, 498.7 (169.1 to 828.2) for bupro-
pion, and 751.7 (627.4 to 876.0) for nicotine
replacement products.
The age and sex adjusted hazard ratio for self harm
associated with prescribed varenicline was similar to
that for bupropion, and the hazard ratios suggest a
lower risk of self harm than that associated with nico-
tine replacement products, although the confidence
intervals were wide and included 1.00 (table 2). After
controllingfor possibleconfoundingfactors, we found
very weak evidence of an increased risk in relation to
both varenicline (hazard ratio 1.12 (0.67 to 1.88)) and
bupropion (hazard ratio 1.17 (0.59 to 2.32)). The con-
founding factors that most strongly contributed to the
change in direction of the association with varenicline
were past and current use of antidepressants. There
wasnostatisticalevidencethatassociationsofsmoking
cessation products with self harm differed by sex
(P(interaction)=0.74), age (P(interaction)=0.70), the
timing of the prescribing (before or after media publi-
city around January 2008) (P(interaction)=0.32), or
past psychiatric problems (P(interaction)=0.96).
In fully adjusted models varenicline was associated
with a 43% (95% confidence interval −47% to 285%)
increased risk of suicidal thoughts compared with
nicotine replacement products. However, the wide
confidence intervals were consistent with a large pro-
tective effect, no effect, or a large adverse effect.
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Of the 64296 patients not taking antidepressants at
baseline, 2244 (3.5%) were treated for depression
over the follow-up period. Among these patients
there was no evidence in either age and sex adjusted
orfullyadjustedmodelsthatvareniclinewasassociated
withanincreasedriskofdevelopingtreateddepression
compared with nicotine replacement products, and
major increases in risk can be ruled out (hazard ratio
0.88 (0.77 to 1.00), table 2).
Sensitivity analyses and all-cause mortality
The risk of self harm and depression with varenicline
and bupropion compared with nicotine replacement
products were essentially unchanged in (a) models
restricted to people who took only one smoking
cessation product after 1 September 2006, with
adjusted hazard ratios for self harm in relation to var-
enicline 1.12 (95% confidence interval 0.67 to 1.88)
and in relation to bupropion 1.29 (0.63 to 2.66); and
(b) models censoring follow-up to 10 weeks after treat-
ment started for all subjects (adjusted hazard ratios for
self harm in relation to varenicline 0.93 (0.49 to 1.76)
and bupropion (1.10 (0.50 to 2.38)).
Overall208participantsdiedoverthefollow-upper-
iod. In age and sex adjusted models we found no evi-
dence that either varenicline or bupropion were
associated with an increased risk of all cause mortality
risk compared with nicotine replacement therapy
(hazard ratios 0.26 (0.13 to 0.53) and 0.56 (0.26 to
1.19) respectively).
Table 1 |Comparison of baseline characteristics of people prescribed different smoking cessation therapies. Values are










Male sex 27 780 (43.9) 3109 (48.4) 5109 (46.6) 35 998 (44.6)
Median age (years) 45.80 43.29 45.91 45.52
Previous mental health consultation 2563 (4.1) 156 (2.4) 279 (2.5) 2998 (3.7)
Alcohol misuse 6702 (10.6) 468 (7.3) 909 (8.3) 8079 (10.0)
Hypnotics use:
None 38 682 (61.1) 4205 (65.5) 6824 (62.2) 49 711 (61.6)
Previous 15 604 (24.7) 1561 (24.3) 3043 (27.7) 20 208 (25.1)
Current 8979 (14.2) 656 (10.2) 1106 (10.1) 10 741 (13.3)
Antipsychotic use:
None 49 592 (78.4) 5491 (85.5) 9038 (82.4) 64 121 (79.5)
Previous 9837 (15.6) 775 (12.1) 1660 (15.1) 12 272 (15.2)
Current 3836 (6.1) 156 (2.4) 275 (2.5) 4267 (5.3)
Antidepressant use:
None 31 174 (49.3) 3610 (56.2) 5648 (51.5) 40 432 (50.1)
Previous 16 107 (25.5) 1819 (28.3) 3344 (30.5) 21 270 (26.4)
Current 15 984 (25.3) 993 (15.5) 1981 (18.1) 18 958 (23.5)
Previous suicide related event 6985 (11.0) 563 (8.8) 1041 (9.5) 8589 (10.7)
Previous smoking cessation therapy 30 640 (48.4) 3518 (54.8) 5725 (52.2) 39 883 (49.4)
Median No of clinical visits per year 3.18 2.71 2.83 3.09
Exposed to treatment before January 2008 52 953 (83.7) 5720 (89.1) 6378 (58.1) 65 051 (80.7)
Index of multiple deprivation score:
0 10 289 (16.3) 1110 (17.3) 1566 (14.3) 12 965 (16.1)
1 10 230 (16.2) 1249 (19.4) 1968 (17.9) 13 447 (16.7)
2 12 512 (19.8) 1262 (19.7) 1877 (17.1) 15 651 (19.4)
3 13 536 (21.4) 1364 (21.2) 1980 (18.1) 16 880 (20.9)
4 16 698 (26.4) 1437 (22.4) 3582 (32.6) 21 717 (26.9)
UK region:
England 49 521 (78.3) 5523 (86.0) 8409 (76.6) 63 453 (78.6)
Northern Ireland 2822 (4.5) 109 (1.7) 602 (5.5) 3533 (4.4)
Scotland 4460 (7.0) 425 (6.6) 1306 (11.9) 6191 (7.7)
Wales 6462 (10.2) 365 (5.7) 656 (6.0) 7483 (9.3)
No of smoking cessation drugs used*:
1 59 109 (93.4) 5023 (78.2) 10 207(93.0) 74 339 (92.2)
2 4023 (6.4) 1272 (19.8) 749 (6.8) 6044 (7.5)
3 133 (0.2) 127 (2.0) 17 (0.2) 277 (0.3)
*Including initial study treatment.
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Main findings
We found no clear evidence of an increased risk of self
harmassociatedwith varenicline comparedwith other
smokingcessationproducts,althoughthelimitedstudy
power means we cannot rule out either a halving or a
twofold increase in risk. Analysis of those patients pre-
scribed varenicline suggested that they were likely to
beatlowerriskofselfharmthanthoseprescribednico-
tine replacement products—they had lower levels of
past psychiatric consultation and previous self harm.
Nevertheless,controllingforthesefactorsinmultivari-
ablemodelsdidnotalterourconclusions.Wefoundno
evidence that varenicline increased the incidence of
suicidal thoughts. However, associations with suicidal
thoughts should be treated with caution as they are
under-recorded in the General Practice Research
Database (GPRD). Varenicline was associated with a
reducedriskoftreateddepression,asindexedbyinitia-
tion of antidepressant therapy.
Strengths and limitations of study
The GPRD contains detailed records of prescribing
and health related events for a large number of people
registered with general practitioners in the United
Kingdom and so can provide timely information con-
cerning emerging drug safety concerns. Detailed data
on patient sociodemographics and medical history
enable assessment of possible confounding.
There are several limitations to this analysis. Firstly,
study power was limited: despite the large coverage of
the GPRD, we identified only 10973 people pre-
scribed varenicline over the study period, and only
18 episodes of self harm were recorded in this group.
Secondly, our analysis is restricted to products pre-
scribed in primary care. Patients receiving smoking
cessation products in NHS smoking cessation clinics
or buying over the counter products from pharmacies
will be excluded. People who visit their general practi-
tioner for prescriptions of smoking cessation products
may differ from those attending specific smoking ces-
sationclinics,meaningfindingsmaynotbegeneralisa-
ble to the wider population of people taking smoking
cessation aids.
Thirdly, people taking varenicline and bupropion
may be more likely to have already tried (and failed)
tostopsmokingwithnicotinereplacementtherapyand
so differ in underlying characteristics or level of addic-
tion (and possibly suicide risk) compared with those
prescribednicotine replacement products.Such a pos-
sibility is supported by our observation that those pre-
scribed varenicline or bupropion had slightly higher
levels of previous use of smoking cessation products
(52% and 55% respectively) than those prescribed
nicotine replacement products (49%).
Fourthly, bupropion is licensed for the treatment of
depression in some countries (but not the UK). It is
possible (though unlikely) that some bupropion pre-
scribing is off-label use for depression. Such an effect
wouldexaggerateanyincreasedsuicideriskassociated
with bupropion.
Fifthly, this is an observational study, and the small
differences (or lack of differences) between products
could be due to uncontrolled confounding. We found
some evidence of this in our fully adjusted models,
where the lower risks of self harm associated with var-
enicline in our age and sex adjusted models were
reversed.
Lastly, full death certificates were not obtained for
studymemberswhodied,possiblyleadingtoanunder-
estimation of suicide deaths. The ratio of episodes of
non-fatalselfharmtosuicideinthegeneralpopulation
(and in our previous GPRD study
9) is around 20-30:1,
but it is 80:1 in our current study, indicating that we
may have failed to identify some cases of suicide.
Such an effect is unlikely to bias our results, as cause
of death certification should be non-differential with
respect to smoking cessation product. Furthermore,
as there are 20-30 episodes of non-fatal self harm for
every suicide death, any under-numeration will have
little impact on the precision of our effect estimates.
Similarly,therelativelylownumberofcasesofsuicidal
thoughts (n=37) suggests these were under-recorded:
in the general population the incidence of suicidal





at two to three times greater risk of suicide than non-
smokers.
56 Possible explanations for this increase in
risk
2 include (a) smoking may be used as “self medica-
tion” by people with mental illness, and such people
are at increased risk of suicide; (b) confounding by
factors such as low socioeconomic position, alcohol
misuse, and psychiatric illness, all of which are asso-
ciated with increased smoking prevalence and suicide
Table 2 |Relative risks of fatal and non-fatal self harm, suicidal thoughts, and depression in
people prescribed different smoking cessation products*
Smoking cessation
product
No of events/No of people
prescribed the product
Hazard ratio (95% CI)
Adjustedforageandsex Fully adjusted†
Fatal and non-fatal self harm
Nicotine replacement 141/63 265 1.0 1.0
Bupropion 9/6422 0.66 (0.33 to 1.29) 1.17 (0.59 to 2.32)
Varenicline 18/10 973 0.71 (0.43 to 1.16) 1.12 (0.67 to 1.88)
Suicidal thoughts
Nicotine replacement 30/63 265 1.0 1.0
Bupropion 2/6422 0.69 (0.16 to 2.90) 1.20 (0.28 to 5.12)
Varenicline 5/10 973 0.94 (0.36 to 2.42) 1.43 (0.53 to 3.85)
Start of antidepressant therapy‡ ‡
Nicotine replacement 1792/49 415 1.0 1.0
Bupropion 160/5719 0.86 (0.73 to 1.01) 0.91 (0.77 to 1.07)
Varenicline 292/9162 0.82 (0.72 to 0.93) 0.88 (0.77 to 1.00)
*Risks calculated from Cox proportional hazards regression model.
†Adjusted for age; sex; use of hypnotics, antipsychotics, and antidepressants; alcohol misuse; previous suicide
related event; previous smoking cessation therapy; psychiatric consultation; date of initial exposure to product,
number of general practice visits per year, index of multiple deprivation, UK region.
‡Restricted to those with no antidepressants in the six months before smoking cessation therapy.
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1213; and (c) smoking may cause psychological ill-
ness and physical health problems, both of which are
associated with suicide risk. In studies that have con-
trolled for a wide range of social and mental health




give up smoking) are a high risk group.
Smoking is common amongpeople with psychiatric
illness,
13 and it is possible that it has a beneficial effect
on psychiatric symptoms, such as anxiety, that may be
lost with smoking cessation. Furthermore, as smoking
is addictive, smoking cessation leads to unpleasant
withdrawal symptoms. Thus, reported associations of
psychiatric symptoms and self harm with varenicline
and bupropion may be confounded by the effects of
smoking cessation or influenced by the fact that smo-
kers are a high risk group. Nevertheless, it is note-
worthy that in a review of adverse outcomes
associatedwithsmokingcessationinthreerandomised
trials of interventions that achieved more than a 10%
reduction in smoking in the intervention arm com-
pared with controls, those in the intervention arm
had a reduced risk of suicide at follow-up (odds ratio
0.56 (95% confidence interval 0.26 to 1.21)).
15 These
trials involved lifestyle interventions to reduce cardio-
vascular risk as well as smoking cessation advice or
treatment and all preceded the introduction of vareni-
cline and bupropion.
Clinical trials show that the most commonly
reported adverse effect of varenicline is nausea—
reported by about a quarter of patients.
1 Possible
adverse effects of varenicline on mood and suicidal
thoughts do not seem to have been systematically
assessed in the larger placebo controlled trials of this
product.
1617However,thesetrialsfindnoevidenceofa
greater adverse effect of varenicline on sleep or irrit-
ability compared with placebo, though there is evi-
dence that varenicline increases the incidence of vivid
dreamsandincreasedfrequencyofdreams.Inourana-
lysis, those receiving varenicline were less likely to
initiate antidepressant therapy over the follow-up per-
iod than those prescribed nicotine replacement pro-
ducts (fully adjusted hazard ratio 0.88 (0.77 to 1.00)).
There are several possible explanations for this find-
ing.Firstly,it maybeduetochance.Secondly,general
practitioners may be less willing to prescribe anti-
depressants to patients already prescribed varenicline
orbupropionthantothoseprescribedanicotinerepla-
cement product. Thirdly, in view of the warnings on
the risk of suicide, general practitioners were encour-




we did not control for in our analysis—the presence of
such factors is suggested by the lower all cause mortal-
ity in people prescribed varenicline compared with
those prescribed nicotine replacement products.




We found no clear evidence of an increased risk of self
harm, suicidal thoughts, or depression in people pre-
scribed varenicline compared with those prescribed
other smoking cessation products. In view of increas-
ing concerns about the possible increased risk of sui-
cide associated with these drugs and their increasing
popularity, further investigation of their effect on sui-
cide risk is required in other databases and through
secondary analysis of all adverse event reporting in
relevant clinical trials. Any such risk must be balanced
against the likely long term health benefits of smoking
cessation and the robust evidence of the effectiveness
of varenicline as an aid to smoking cessation.
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